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I
n the late 1950s, the late 
Democratic Senator Estes 
Kefauver, Chairman of the 
United States Senate’s Anti-Trust 
and Monopoly Subcommittee, put 
together the first extensive indictment 
against the business workings of the 
pharmaceutical industry. He laid three 
charges at the door of the industry: 
(1) Patents sustained predatory prices 
and excessive margins; (2) Costs and 
prices were extravagantly increased by 
large expenditures in marketing; and 
(3) Most of the industry’s new products 
were no more effective than established 
drugs on the market [1]. Kefauver’s 
indictment against a marketing-driven 
industry created a representation of the 
pharmaceutical industry far different 
than the one offered by the industry 
itself. As Froud and colleagues put it, 
the image of life-saving “researchers in 
white coats” was now contested by the 
one of greedy “reps in cars” [2]. The 
outcome of the struggle over the image 
of the industry is crucial because of its 
potential to influence the regulatory 
environment in which the industry 
operates. 
Fifty years later, the debate still 
continues between these two depictions 
of the industry. The absence of reliable 
data on the industry’s cost structures 
allows partisans on both sides of the 
debate to cite figures favorable to their 
own positions. The amount of money 
spent by pharmaceutical companies on 
promotion compared to the amount 
spent on research and development is 
at the heart of the debate, especially in 
the United States. A reliable estimate 
of the former is needed to bridge the 
divide between the industry’s vision 
of research-driven, innovative, and 
life-saving pharmaceutical companies 
and the critics’ portrayal of an 
industry based on marketing-driven 
profiteering. 
IMS, a firm specializing in 
pharmaceutical market intelligence, 
is usually considered to be the 
authority for assessing pharmaceutical 
promotion expenditures. The US 
General Accounting Office, for 
example, refers to IMS numbers in 
concluding that “pharmaceutical 
companies spend more on research 
and development initiatives than on 
all drug promotional activities” [3]. 
Based on the data provided by IMS 
[4], the Pharmaceutical Research and 
Manufacturers of America (PhRMA), 
an American industrial lobby group 
for research-based pharmaceutical 
companies, also contends that 
pharmaceutical firms spend more on 
research and development (R&D) than 
on marketing: US$29.6 billion on R&D 
in 2004 in the US [5] as compared to 
US$27.7 billion for all promotional 
activities.[4] 
In this paper, we make the case 
for the need for a new estimate of 
promotional expenditures. We then 
explain how we used proprietary 
databases to construct a revised 
estimate and finally, we compare our 
results with those from other data 
sources to argue in favor of changing 
the priorities of the industry.
The Case for a New Estimate of 
Pharmaceutical Promotion
There are many concerns about 
the accuracy of the IMS data. First, 
IMS compiles its information 
through surveys of firms, creating 
the possibility that companies may 
systematically underestimate some of 
their promotional costs to enhance 
their public image. Second, IMS does 
not include the cost of meetings and 
talks sponsored by pharmaceutical 
companies featuring either doctors 
or sales representatives as speakers. 
The number of promotional meetings 
has increased dramatically in recent 
years, going from 120,000 in 1998 to 
371,000 in 2004 [6]. In 2000, the top 
ten pharmaceutical companies were 
spending just under US$1.9 billion on 
314,000 such events [7]. Third, IMS 
does not include the amount spent 
on phase IV “seeding” trials, trials 
designed to promote the prescription 
of new drugs rather than to generate 
scientific data. In 2004, 13.2% (US$4.9 
billion) of R&D expenditures by 
American pharmaceutical firms was 
spent on phase IV trials [5]. Almost 
75% of these trials are managed solely 
by the commercial, as opposed to the 
clinical, division of biopharmaceutical 
companies, strongly suggesting that the 
vast majority of these trials are done 
just for their promotional value [8]. 
Finally, IMS data seem inconsistent 
with estimates based on the 
information in the annual reports 
of pharmaceutical companies. For 
example, in an accounting study based 
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on the annual reports of ten of the 
largest global pharmaceutical firms, 
Lauzon and Hasbani showed that 
between 1996 and 2005, these firms 
globally spent a total of US$739 billion 
on “marketing and administration.” 
In comparison, these same firms spent 
US$699 billion in manufacturing costs, 
US$288 billion in R&D, and had a net 
investment in property and equipment 
of US$43 billion, while receiving 
US$558 billion in profits [9]. 
Annual reports, however, have their 
own limitations. First, pharmaceutical 
firms are multinational and diversified; 
their annual reports provide no 
information on how much they spend 
on pharmaceutical marketing, as 
compared to the marketing of their 
non-pharmaceutical products, and they 
do not provide information about how 
much is spent on marketing specifically 
in the US. Second, annual reports 
merge the categories of “marketing” 
and “administration,” without 
delineating the relative importance 
of each. Finally, “marketing” is a 
category that includes more than just 
promotion; it also includes the costs of 
packaging and distribution. In terms 
of offering a more precise estimate of 
overall expenditures on pharmaceutical 
promotion in the US, annual reports 
are thus far from satisfactory.
In the absence of any collection 
of information on promotional 
spending by government or any 
other noncommercial source, the 
market research company IMS 
has long been the only source of 
such information, which it gains by 
surveying pharmaceutical firms. Since 
2003, however, the market research 
company CAM has been providing 
comprehensive information on 
promotion expenditures by surveying 
doctors instead of firms. (In July 2005, 
CAM was merged into the Cegedim 
Group, another market research 
company.) We chose to compare 
IMS data to those produced by CAM 
in order to provide a more accurate 
estimate of promotional spending in 
the US. Other proprietary sources of 
data do not break down promotional 
expenditures into different categories 
and therefore were not used in our 
comparison.
Methods 
According to its Web site (http://
www.imshealth.com/), IMS 
provides business intelligence and 
strategic consulting services for the 
pharmaceutical and health care 
industries. It is a global company 
established in more than 100 countries. 
IMS gathers data from 29,000 data 
suppliers at 225,000 supplier sites 
worldwide. It monitors 75% of 
prescription drug sales in over 100 
countries, and 90% of US prescription 
drug sales. It tracks more than 1 million 
products from more than 3,000 active 
drug manufacturers. IMS data for 2004 
were obtained from its Web site for 
the amount spent on: visits by sales 
representatives (detailing), samples, 
direct-to-consumer advertising, and 
journal advertising.
The Cegedim Web site (http://www.
cegedim-crm.com/index.php?id=12) 
describes CAM as a global company 
dedicated to auditing promotional 
activities of the pharmaceutical 
industry, established in 36 countries 
worldwide. CAM annually surveys 
a representative sample of 2,000 
primary care physicians and 4,800 
specialists in a variety of specialties 
in selected locations in the US. From 
CAM’s newsletter [10], we obtained 
access to data from CAM for the same 
promotion categories as from IMS. In 
addition, CAM provided figures for 
the amount of spending on company-
sponsored meetings, e-promotion, 
mailings, and clinical trials. 
We used 2004 as the comparison 
year because it was the latest year for 
which information was available from 
both organizations. We focused on the 
US because it is the only country for 
which information is available for all 
important promotional categories. The 
US is also, by far, the largest market 
for pharmaceuticals in the world, 
representing around 43% of global 
sales [11,12] and global promotion 
expenditures [10,13].
We asked both CAM and IMS 
about the procedures that they used 
to collect information on different 
aspects of promotion. Based on the 
answers we received, we determined 
the relevant figures for expenditures 
for samples and detailing. Each 
author independently decided on 
which values should be used, based 
on an understanding of the methods 
that the companies used to collect 
the information and the limitations 
of those methods. Differences were 
resolved by consensus. 
We queried CAM and IMS about 
the estimated value of unmonitored 
promotional expenditures. IMS did 
not provide an answer to this question. 
In order to validate its estimates, CAM 
relies on a validation committee that 
includes representatives from various 
pharmaceutical firms, including 
Merck, Pfizer, Bristol-Myers Squibb, 
Eli Lilly, Aventis, Sanofi-Synthelabo, 
AstraZeneca, and Wyeth. Under 
a confidentiality agreement, the 
firms supply CAM with internal data 
related to their detailing activity and 
promotional costs in the US. Through 
the validation committee, CAM 
can thus compare totals obtained 
through its own audits with the firms’ 
internal data about their promotional 
budgets in order to evaluate if all 
promotion has been properly audited 
through its physician surveys. As a 
result of this comparison, CAM’s 
validation committee considers that 
about 30% of promotional spending 
is not accounted for in its figures. 
CAM is unable to provide an exact 
breakdown of unmonitored promotion, 
Table 1. Pharmaceutical Marketing Expenditures in the United States in 2004:  
Data from IMS, CAM, and Our New Estimate
Type of Promotion IMS  (US$ 
Billions)
CAM (US$ 
Billions)
New Estimate 
(US$ Billions)
Percent of Total 
of New Estimate
Samples 15.9 6.3 15.9 (IMS) 27.7
Detailing 7.3 20.4 20.4 (CAM) 35.5
DTCA (Data provided by CMR) 4 4 4 (CMR) 7
Meetings nd 2 2 (CAM) 3.5
E-promotion, mailing, clinical trials nd 0.3 0.3 (CAM) 0.5
Journal advertising 0.5 0.5 0.5 (CAM/IMS) 0.9
Unmonitored promotion  (estimatea) nd 14.4 14.4 (CAM) 25
Total 27.7 47.9 57.5 100
aIncludes incomplete disclosure and omissions by surveyed physicians, promotion to unaudited physician categories, 
promotion in unmonitored journals, and could possibly include unethical forms of promotion funded out of the firms’ 
marketing budget. See text for details about this category.
DTCA, direct-to-consumer advertising; nd, no data
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but it believes that around 10% is 
due to incomplete disclosure and 
omissions by surveyed physicians and 
the remaining 20% comes from a 
combination of promotion directed 
at categories of physicians that are 
not surveyed, unmonitored journals 
in which pharmaceutical promotion 
appears, and possibly unethical 
forms of promotion. We adjusted 
total expenditures to account for this 
unreported 30%. 
Results
For 2004, CAM reported total 
promotional spending in the US of 
US$33.5 billion [10], while IMS gave 
the figure of US$27.7 billion for the 
same year [4]. Both CAM and IMS 
cited the media intelligence company 
CMR as the source for the amount 
spent on direct-to-consumer advertising 
(US$4 billion), and they also gave the 
same figure for journal advertising 
(US$0.5 billion).
There were two major differences 
between the two sets of figures: the 
amounts spent on detailing and 
the amounts spent on samples. 
IMS estimated the amount spent 
on detailing at US$7.3 billion [4] 
versus US$20.4 billion for CAM [10], 
and while IMS gave a retail value of 
US$15.9 billion for samples [14], CAM 
estimated a wholesale value of US$6.3 
billion [10].
Using the IMS figure of US$15.9 
billion for the retail value of samples, 
and adding the CAM figures for 
detailing and other marketing expenses 
after correcting for the 30% estimate 
of unaccounted promotion, we arrived 
at US$57.5 billion for the total amount 
spent in the US in 2004, more than 
twice what IMS reported (see Table 1). 
Discussion
Our revised estimate for promotional 
spending in the US is more than twice 
that from IMS. This number compares 
to US$31.5 billion for domestic 
industrial pharmaceutical R&D 
(including public funds for industrial 
R&D) in 2004 as reported by the 
National Science Foundation [15]. 
However, even our revised figure 
is likely to be incomplete. There are 
other avenues for promotion that 
would not be captured by either IMS 
or CAM, such as ghostwriting [16] 
and illegal off-label promotion [17]. 
Furthermore, items with promotional 
potential such as “seeding trials” or 
educational grants might be included 
in other budgets and would not be seen 
in the confidential material provided to 
CAM’s validation committee. 
IMS and CAM data were used for 
comparison purposes for a number of 
reasons: data from both were publicly 
available, both operate on a global 
scale and are well regarded by the 
pharmaceutical industry, both break 
down their information by different 
categories of promotion, and, most 
importantly, they use different methods 
for gathering their data, thereby 
allowing us to triangulate on a more 
accurate figure for each category. 
Methodological differences between 
the ways that IMS and CAM collect data 
will affect the values for promotional 
spending depending on the category 
being considered. Because of the 
problematic nature of some data from 
each firm, we believe that the most 
precise picture of industry spending 
can be obtained by selectively using 
both sets of figures.
CAM compiles its data on the value 
of detailing and samples through 
systematic surveys of primary care 
providers and specialists and by 
estimating an average cost for each 
visit by a sales representative according 
to the type of physician. By contrast, 
IMS compiles its data on the value 
of detailing through surveys of firms, 
while its data on samples are obtained 
by monitoring products directly from 
manufacturers. 
There is a significant discrepancy 
between the two sets of data in the cost 
of detailing: US$7.3 billion for IMS 
and US$20.4 billion for CAM. This 
difference can be explained by the fact 
that CAM offers a more complete data 
set since it includes in the average cost 
of a call (a sales representative’s visit to 
a physician) not only the “cost to field 
the rep” (salary and benefits of the 
representative and the transportation 
cost) but also the costs for the area 
and regional managers, the cost of the 
training, and the cost of detail aids such 
as brochures and advertising material. 
By contrast, in reporting the cost of 
detailing IMS only considers the “cost 
to field the rep.” Furthermore, relying 
on physician-generated data to estimate 
the amount spent on detailing is likely 
to give a more accurate figure than 
using figures generated by surveying 
firms. Companies may not report some 
types of detailing, for example, the 
use of sales representatives for illegal 
off-label promotion, whereas doctors 
are not likely to distinguish between 
on- and off-label promotion and 
would report all encounters with sales 
representatives.
In the case of samples, there is 
also a large difference between the 
IMS (US$15.9 billion) and CAM 
(US$6.3 billion) estimates. CAM 
estimates the amount spent on 
samples by multiplying the number 
of samples declared by physicians 
with their wholesale value. The latter 
is determined by using the average 
wholesale price (AWP), which is the 
amount set by manufacturers and used 
by Medicare in the US to determine 
reimbursement. CAM then divides that 
amount in half to account for the fact 
that samples are frequently given out 
in small dosage forms. CAM admits, 
however, that the amount for samples is 
understated because, when physicians 
fill out their survey, any quantity of 
samples of the same product left 
during a call is considered to be only 
one sample unit. CAM’s calculations 
also rely on the AWP, which has been 
criticized for not taking into account 
the various discounts and rebates that 
are negotiated between manufacturers 
and purchasers [18]. 
IMS provides exact figures for the 
retail value for samples by monitoring 
90% of all pharmaceutical transactions 
and by tracking products directly 
from manufacturers. This method 
for calculating the value of samples 
is much more direct than CAM’s and 
therefore is likely to be subject to less 
error. 
Using the wholesale value for 
samples, the CAM figure would be 
appropriate if we were arguing that 
the money spent on samples should 
go to another activity such as R&D. 
However, we have used the retail value 
of samples because this is consistent 
with companies’ reporting of drugs 
they donate [19]. As these are both 
categories of products that are being 
distributed without a charge to the 
user, it is inconsistent for donations to 
be reported in terms of retail value and 
samples in terms of wholesale value.
We believe that it is appropriate to 
correct for unmonitored promotion 
and that the figure we used is a reliable 
estimate. The 30% correction factor 
is based on a direct comparison that PLoS Medicine  |  www.plosmedicine.org 0032 January 2008  |  Volume 5  |  Issue 1  |  e1
CAM is able to make between the data 
it collects through its surveys and the 
amount reported by companies.
There are other ways of combining 
the data that we have presented, 
but with the exception of choosing 
the lower amounts for detailing 
and samples and ignoring the 30% 
for unmonitored promotion, all of 
them yield a higher figure than the 
one from IMS. Some examples of 
alternative estimates follow: using the 
CAM estimate for the wholesale value 
of samples and the 30% adjustment, 
the total amount would be US$47.9 
billion; without the 30% adjustment 
CAM’s estimate is US$33.5 billion. 
Adding the figures for the categories 
that IMS does not cover (meetings, 
e-promotion, mailing, clinical trials) 
boosts its estimate to US$31 billion; 
using the lower figures for detailing 
and samples plus the CAM amounts for 
the other categories and applying the 
30% adjustment gives an amount of 
US$29.1 billion. Therefore, the actual 
amount could range from a low of 
US$27.7 billion to a high of US$57.5 
billion. Our analysis shows, however, 
that the figure of US$57.5 billion is the 
most appropriate one when using the 
most relevant figures for each category 
of promotional spending. 
Excluding direct-to-consumer 
advertising, CAM considers that around 
80% of the remaining promotion is 
directed towards physicians, with 20% 
of this figure going to pharmacists. 
(IMS does not provide any comparable 
values.) With about 700,000 practicing 
physicians in the US in 2004 [20], we 
estimate that with a total expenditure 
of US$57.5 billion, the industry spent 
around US$61,000 in promotion 
per physician. As a percentage of US 
domestic sales of US$235.4 billion [21], 
promotion consumes 24.4% of the sales 
dollar versus 13.4% for R&D.
Our new estimate of total promotion 
costs and promotion as a percentage 
of sales is broadly in line with estimates 
of promotional or marketing spending 
from other sources. The annual reports 
of Novartis distinguish “marketing” 
from “administration.” Marcia Angell 
extrapolates from this annual report 
to the entire industry and calculates 
a figure of US$54 billion spent on 
pharmaceutical promotion in the 
US in 2001 [22]. As a proportion of 
sales, she estimates 33% is spent on 
marketing. Using similar methodology, 
the Office of Technology Assessment 
derived an estimate for marketing costs 
in the US by extrapolating from the 
cost structure of Eli Lilly. The Office 
of Technology Assessment considers 
that firms spend around 22.5% of their 
sales on marketing [23]. Based on 
United Nations Industrial Development 
Organization estimates, a report 
from the Organization for Economic 
Cooperation and Development 
estimated that, in 1989, pharmaceutical 
firms globally spent 24% of their sales 
on marketing [24], but few details of 
the methodology used were provided, 
making it impossible to verify the 
accuracy of the estimate. Finally, in 
2006 Consumers International surveyed 
20 European pharmaceutical firms to 
obtain more information about their 
exact expenditures on drug promotion. 
Among the 20 firms contacted, only 
five agreed to provide separate figures 
for marketing, which ranged from 31% 
to 50% of sales depending on the firm 
[25]. 
The results are also consistent with 
data on the share of revenue allocated 
to “marketing and administration” 
according to annual reports of large 
pharmaceutical companies, if we 
consider that the largest part of 
“marketing and administration” is 
devoted to promotion. Lauzon and 
Hasbani found that 33.1% of revenues 
was allocated to “marketing and 
administration” [9], similar to the 31% 
reported by the Centers for Medicare 
and Medicaid Services [26] and the 
27% from Families USA [27].
The value of our estimate over 
these others is that it is not based on 
extrapolating from annual reports 
of firms that are both diversified and 
multinational. Our estimate is driven 
by quantifiable data from highly 
reliable sources and concerns only the 
promotion of pharmaceutical products 
in the US. The derivation of our figure 
is thus transparent and can form the 
basis for a vigorous debate. 
Conclusion
From this new estimate, it appears 
that pharmaceutical companies 
spend almost twice as much on 
promotion as they do on R&D. These 
numbers clearly show how promotion 
predominates over R&D in the 
pharmaceutical industry, contrary to 
the industry’s claim. While the amount 
spent on promotion is not in itself a 
confirmation of Kefauver’s depiction 
of the pharmaceutical industry, 
it confirms the public image of a 
marketing-driven industry and provides 
an important argument to petition in 
favor of transforming the workings of 
the industry in the direction of more 
research and less promotion. ◼
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